Abstract
There is a growing body of evidence that the formation and accumulation of advanced glycation end products (AGE) have been known to progress under diabetic conditions, thereby being involved in diabetic vascular complications. Further, we, along with others, have recently found AGE could disturb insulin actions in cultured adipocytes and skeletal muscles. However, the pathological role of AGE in insulin resistance in vivo is not fully understood. Therefore, in this study, we examined whether pyridoxamine, an inhibitor of AGE formation could ameliorate insulin resistance in KK-Ay mice, a model animal of obese, type 2 diabetes. Fasting blood glucose, serum levels of insulin and AGE in KK-Ay mice were elevated as the mice got older (from 5 weeks old to 15 weeks old). Serum levels of AGE were positively correlated with insulin (R2=0.3956, P=0.002) in KK-Ay mice. Administration of pyridoxamine dose-dependently decreased fasting insulin levels and improved insulin sensitivity in KK-Ay mice of 10 weeks old, although it did not affect fasting blood glucose levels. Our present study suggests the involvement of AGE in insulin resistance in KK-Ay mice. Inhibition of AGE formation may be a novel therapeutic target for improving insulin resistance in diabetes with obesity.
Keywords: AGE, insulin resistance, diabetes
Protein & Peptide Letters
Title: Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice
Volume: 17 Issue: 9
Author(s): Hiroyuki Unoki-Kubota, Sho-ichi Yamagishi, Masayoshi Takeuchi, Hideaki Bujo and Yasushi Saito
Affiliation:
Keywords: AGE, insulin resistance, diabetes
Abstract: There is a growing body of evidence that the formation and accumulation of advanced glycation end products (AGE) have been known to progress under diabetic conditions, thereby being involved in diabetic vascular complications. Further, we, along with others, have recently found AGE could disturb insulin actions in cultured adipocytes and skeletal muscles. However, the pathological role of AGE in insulin resistance in vivo is not fully understood. Therefore, in this study, we examined whether pyridoxamine, an inhibitor of AGE formation could ameliorate insulin resistance in KK-Ay mice, a model animal of obese, type 2 diabetes. Fasting blood glucose, serum levels of insulin and AGE in KK-Ay mice were elevated as the mice got older (from 5 weeks old to 15 weeks old). Serum levels of AGE were positively correlated with insulin (R2=0.3956, P=0.002) in KK-Ay mice. Administration of pyridoxamine dose-dependently decreased fasting insulin levels and improved insulin sensitivity in KK-Ay mice of 10 weeks old, although it did not affect fasting blood glucose levels. Our present study suggests the involvement of AGE in insulin resistance in KK-Ay mice. Inhibition of AGE formation may be a novel therapeutic target for improving insulin resistance in diabetes with obesity.
Export Options
About this article
Cite this article as:
Unoki-Kubota Hiroyuki, Yamagishi Sho-ichi, Takeuchi Masayoshi, Bujo Hideaki and Saito Yasushi, Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice, Protein & Peptide Letters 2010; 17 (9) . https://dx.doi.org/10.2174/092986610791760423
DOI https://dx.doi.org/10.2174/092986610791760423 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in the Treatment of Alcoholic Chronic Pancreatitis
Current Drug Abuse Reviews Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder
Current Psychiatry Reviews mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) Anti-Diabetic Effects of Isolated Lipids from Natural Sources through Modulation of Angiogenesis
Current Molecular Pharmacology Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery HDL as a Target for Glycemic Control
Current Drug Targets A Possible Target of Antioxidative Therapy for Diabetic Vascular Complications-Vascular NAD(P)H Oxidase
Current Medicinal Chemistry Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews An Angiotensin Converting Enzyme Inhibitor Suppresses Contrast Media Induced Renal Dysfunction in a Murine Model of Subtotal Nephrectomy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy Interaction Between Genetic Polymorphisms in Renin-Angiotensin System (RAS) and Therapeutic Efficacy of RAS Blockade in IgA Nephropathy
Current Pharmacogenomics Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Kinetic Spectrophotometric Determination of Betaxolol, Clopidogrel and Imidapril in Pharmaceutical Preparations
Current Analytical Chemistry Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology